Navigation Links
Long Term Data Presented at EuroPCR 2009 from Randomized Study Attest to Durability of Results of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) Compared to Drug-Eluting Stents
Date:5/20/2009

Other Presentations Highlight Pre-clinical Work of Company's Future Pro-healing Technologies

BARCELONA, Spain, May 20 /PRNewswire/ -- OrbusNeich announced today that two year follow up data from a single center, randomized clinical study in patients at high risk of restenosis were presented at EuroPCR 2009, demonstrating stable results in patients treated with the company's Genous Bio-engineered R stent, the world's first pro-healing stent, compared with results from patients treated with a drug-eluting stent.

Presented by Marcel Beijk, M.D., of the Academic Medical Center in Amsterdam, two year follow up data from the single center TRIAS HR (high risk) study show similar mortality (5.1% vs 4.2%) and target lesion revascularization (TLR) rates (15.3% vs 13.7%) for the Genous Bio-engineered R stent compared to Boston Scientific's Taxus(R) Liberte stent in high risk of restenosis patients. However, the thrombosis rate for Taxus treated patients increased from one to two years from 4.2% to 5.3%, with another event occurring at 658 days in a patient who had previously presented with a subacute thrombosis and who was on dual antiplatelet therapy at the time of both thromboses. There were no thrombotic events in the Genous treated group at any time period (0.0%). Myocardial infarctions (MI) increased from years one to two in the Taxus patients to 6.3%, while the MI rate in the Genous patients remained steady at 3.1%, all of which were peri-procedural.

"While both groups of patients showed good clinical outcomes, the Genous treated patients were relatively stable between one and two years," said Beijk.

TRIAS HR is a randomized, 193-patient, single-center, prospective study involving patients with a high risk of restenosis. High risk of restenosis is defined as patients who have diabetes mellitus and/or small vessels (less than or equal to 2.8 mm) and/or long lesions (greater than or equal to 23
'/>"/>

SOURCE OrbusNeich
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)
2. Clinical Data on Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, to be Presented at the 2009 ASCO Meeting
3. Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
4. Autism Studies Presented at Mid-Atlantic Research Consortium Meeting
5. Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis
6. New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting
7. Data Presented at AUA Demonstrate PROVENGE Significantly Prolongs Survival for Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
8. Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrines Fully Human Anti-PS Antibody in Prostate Cancer Model
9. Processed Tomato Products May Protect Against Inflammation, According to a Study Presented at the Experimental Biology Meeting
10. Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrines PS-Targeting Antibodies
11. Cequent tkRNAi Technology to be Presented at the Centennial Meeting of the American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Since last month,s FBI shutdown of online drug marketplace ... online black market for illegal drugs - Evolution Marketplace ... drugs and other illegal items.  New numbers from the ... lowering the numbers of drugs and illegal items available ... But some new sites that have emerged as potentially ...
(Date:12/17/2014)... Alemania, December 17, 2014 Los ... con un alto nivel de gasto en investigación y ... 2013/14 (finalizado el 30 de septiembre de 2014) ZEISS ... 4.287 millones de euros (año anterior: 4.190 millones de ... desfavorables. Las ganancias (EBIT) crecieron un 14 por ciento, ...
(Date:12/17/2014)... SCOTTSDALE, Ariz. , Dec. 17, 2014 /PRNewswire/ ... of state-of-the-art interactive music products, today announced that ... Ltd, a leading manufacturer and supplier of innovative ... As part of the agreement, RSL ... Facility bundled solution specifically configured for use within ...
Breaking Medicine Technology:Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 2Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 3ZEISS confirma su posición en un entorno difícil 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3
... onset seizure frequency when, administered as ... ATLANTA, Dec. 3 UCB today ... that its antiepileptic drug (AED) in development,Keppra ... seizure frequency when administered as adjunctive,therapy for ...
... Calif., Dec. 3 Nuvelo, Inc.,(Nasdaq: NUVO ) ... conference,call to discuss results of the Phase 3 SONOMA-2 ... 2),clinical trial presented at the upcoming American Society of ... on Monday, December,10, at 4:30 p.m. Eastern Time (1:30 ...
Cached Medicine Technology:UCB Announces Positive Phase III Trial Results for Keppra XR(TM) (levetiracetam) Extended-Release Tablets 2UCB Announces Positive Phase III Trial Results for Keppra XR(TM) (levetiracetam) Extended-Release Tablets 3UCB Announces Positive Phase III Trial Results for Keppra XR(TM) (levetiracetam) Extended-Release Tablets 4Nuvelo Announces Alfimeprase SONOMA-2 Catheter Occlusion Data Presentation Webcast and Conference Call 2
(Date:12/19/2014)... Novellus Healthcare Communications, LLC announces the ... an independent journal that provides practical information for ... patients inside the pharmacy and retail clinics. ... access to quality care, Inside Patient Care: Pharmacy ... treating and coordinating patient care in pharmacies and ...
(Date:12/19/2014)... 19, 2014 Slone Partners ... personalized medicine, healthcare information technology, and laboratory testing ... of Chief Operating Officer. The announcement comes after ... by a strengthened presence in Boston and several ... lives and breathes the client experience," said Adam ...
(Date:12/19/2014)... Being in good shape seems to reduce your risk of ... from more than 57,000 Americans, including more than 35,000 with ... 2009. Those in the poorest shape had a more ... the start of the study, compared to a 50 percent ... the more than 8,000 people diagnosed with high blood pressure ...
(Date:12/19/2014)... 18, 2014 (HealthDay News) -- Traveling through the same ... virus to three others within a four-hour time span, ... new report shows. "The exposures in this report ... than an international terminal, highlighting the fact that measles ... Vega, an infectious disease specialist at the U.S. Centers ...
(Date:12/17/2014)... Marlborough, Mass. (PRWEB) December 17, 2014 ... College of Osteopathic Medicine (ACOM), which welcomed its ... Virtual Desktop Infrastructure (VDI) to seamlessly support bring ... learning – and teaching – experience. The solution, ... Citrix NetScaler , Dell server and storage ...
Breaking Medicine News(10 mins):Health News:The Transformation of Retail Pharmacies into a Healthcare Delivery Center 2Health News:The Transformation of Retail Pharmacies into a Healthcare Delivery Center 3Health News:Slone Partners Promotes Leslie Loveless to Chief Operating Officer 2Health News:Being Fit Keeps Blood Pressure in Check 2Health News:Arriving Now at Gate 42: Measles 2Health News:Arriving Now at Gate 42: Measles 3Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 3
... , , ... Participacoes S.A.,(Bovespa: AMIL3) ("Amilpar"), in accordance with CVM (the Brazilian ... option to purchase 100% of ESHO - Empresa de Servicos ... Agreement, signed on, October 18, 2007 , in the total ...
... , , SAO PAULO , ... Sao Paulo and London involving Brazilian ethanol group,Cosan ... global,presence for Brazilian sugarcane ethanol. The assessment came from Brazilian,Sugarcane Industry ... In his view, the deal brings together two companies that ...
... New Delhi, Singapore and Washington DC (February 1, 2010) ... children with autism can learn how to teach their ... research published in the January 2010 issue of ... the Hammill Institute on Disabilities and SAGE)., Family members ...
... and then, but that experience can be horrifying for individuals ... that causes them to believe, wrongly, that they appear disfigured ... every tiny blemish looms huge rather than viewing ... researchers at UCLA have determined that the brains of people ...
... include efforts to improve food safety, expand child care ... -- The health-care portion of President Barack Obama,s 2011 ... food-safety program, $1.6 billion to expand child-care programs, and ... Kathleen Sebelius, secretary of Health and Human Services, said ...
... were more likely to delay having sex, , , MONDAY, ... education classes were more likely to delay having sex, a ... 6th- and 7th-grade students, ranging in age from 10 to ... held on Saturdays at four Philadelphia public schools that draw ...
Cached Medicine News:Health News:Amilpar Acquires ESHO 2Health News:Cosan-Shell Deal Expands Global Penetration Outlook for Brazilian Ethanol, Says Brazilian Sugarcane Industry Association 2Health News:Cosan-Shell Deal Expands Global Penetration Outlook for Brazilian Ethanol, Says Brazilian Sugarcane Industry Association 3Health News:Distance education for parents of children with autism found effective 2Health News:Why the mirror lies 2Health News:Obama Proposes $911 Billion for Health and Human Services 2Health News:Obama Proposes $911 Billion for Health and Human Services 3Health News:Abstinence-Only Classes Reduced Sexual Activity, Study Found 2Health News:Abstinence-Only Classes Reduced Sexual Activity, Study Found 3
... designed with the safety and comfort of the ... (also called SF-6) leaded glass, the industry standard ... as set for optical clarity, visible light transmission, ... is protecting your eyes, it also helps you ...
QualCraft™ Euro Lite has a molded nylon frame that fits most faces. Universal keyhole nose bridge fits narrow to average noses. Available with or without lead vinyl-lined side shields....
QualCraft™ Radiation-Reducing Eyewear is 50% lighter than other protective eyewear. Manufactured for the ultimate combination of comfort, function, and protection....
Clip-On Glasses clip onto regular eyewear frames. Plano (nonprescription) only. Will not fit over high-plus or high-minus presciptions, or over glasses with thick frames. Black wire frames. Wt. 63 g....
Medicine Products: